Selz Capital LLC acquired a new stake in CareDx Inc (NASDAQ:CDNA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 81,800 shares of the company’s stock, valued at approximately $1,764,000. Selz Capital LLC owned approximately 0.19% of CareDx as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently modified their holdings of CDNA. State Street Corp increased its stake in shares of CareDx by 26.9% in the 3rd quarter. State Street Corp now owns 2,879,349 shares of the company’s stock worth $65,102,000 after acquiring an additional 609,930 shares during the last quarter. Nuveen Asset Management LLC raised its stake in CareDx by 3,692.4% during the second quarter. Nuveen Asset Management LLC now owns 582,771 shares of the company’s stock worth $20,974,000 after purchasing an additional 567,404 shares during the period. Waddell & Reed Financial Inc. raised its stake in CareDx by 38.9% during the second quarter. Waddell & Reed Financial Inc. now owns 1,849,236 shares of the company’s stock worth $66,554,000 after purchasing an additional 518,218 shares during the period. D. E. Shaw & Co. Inc. raised its stake in CareDx by 228.4% during the second quarter. D. E. Shaw & Co. Inc. now owns 503,099 shares of the company’s stock worth $18,107,000 after purchasing an additional 349,920 shares during the period. Finally, BlackRock Inc. boosted its holdings in CareDx by 14.1% in the 2nd quarter. BlackRock Inc. now owns 2,808,890 shares of the company’s stock valued at $101,091,000 after purchasing an additional 346,085 shares during the last quarter. 96.05% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have recently issued reports on CDNA. Zacks Investment Research downgraded shares of CareDx from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 6th. Piper Jaffray Companies set a $63.00 price target on shares of CareDx and gave the company a “buy” rating in a research report on Friday, November 1st. ValuEngine lowered shares of CareDx from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 24th. BidaskClub lowered shares of CareDx from a “hold” rating to a “sell” rating in a research report on Friday, January 10th. Finally, Craig Hallum initiated coverage on shares of CareDx in a research report on Tuesday, October 1st. They set a “buy” rating and a $48.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $44.17.
NASDAQ CDNA traded down $0.17 on Thursday, reaching $23.18. The stock had a trading volume of 10,277 shares, compared to its average volume of 669,467. The firm has a market capitalization of $978.67 million, a price-to-earnings ratio of -17.82 and a beta of 0.84. CareDx Inc has a 12-month low of $18.75 and a 12-month high of $41.27. The stock has a fifty day moving average price of $21.36 and a two-hundred day moving average price of $25.18.
CareDx (NASDAQ:CDNA) last announced its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. The company had revenue of $33.80 million for the quarter, compared to analyst estimates of $33.14 million. CareDx had a negative return on equity of 21.92% and a negative net margin of 18.25%. The company’s revenue was up 59.4% on a year-over-year basis. On average, sell-side analysts expect that CareDx Inc will post -0.58 earnings per share for the current year.
In other CareDx news, insider Sasha King sold 2,126 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $21.97, for a total value of $46,708.22. Following the sale, the insider now owns 48,709 shares of the company’s stock, valued at $1,070,136.73. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director William A. Hagstrom sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $21.21, for a total value of $265,125.00. 3.20% of the stock is owned by insiders.
CareDx, Inc operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Read More: Certificate of Deposit (CD) For Risk Adverse Investors?
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx Inc (NASDAQ:CDNA).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.